Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Twitter@LouBock

Degrees

San Francisco State University, MBA 1994
Finance
California State University-Chico 1987

Current Companies

Former Companies

Research Associate

Financial Organizations

Web Presences

Tags

Photo Credit

Scale VP

Louis Bock

Lou focuses on identifying emerging biopharmaceutical, device and platform technology companies. He sits on the Boards of Ascenta Therapeutics, Century Hospice, Horizon Pharma, Orexigen Therapeutics, SGX Pharmaceuticals, Sonexa Therapeutics and Zogenix. He is responsible for ScaleVP’s investments in Dynavax Technologies (NASDAQ: DVAX), Prestwick Pharmaceuticals, Seattle Genetics (NASDAQ: SGEN) and Somaxon (NASDAQ: SOMX).

Lou joined ScaleVP in 1997 from Gilead Sciences, where he held positions in research, project management, business development and sales. While at Gilead, Lou was the project manager for Gilead’s approved antiviral drug, Vistide, and was responsible for the discovery of Gilead’s novel thrombin aptamer. Prior to Gilead, he was a research associate at Genentech.

Recent Milestones

Videos

Sources

Edit This Page
Last Edited 1/14/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy